Supplementary Material for: Evaluation of the cytomorphology, immunophenotype, and molecular genetics of lymphoblastic lymphoma/leukemia in serous effusion
收藏DataCite Commons2025-09-29 更新2026-04-25 收录
下载链接:
https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Evaluation_of_the_cytomorphology_immunophenotype_and_molecular_genetics_of_lymphoblastic_lymphoma_leukemia_in_serous_effusion/30230866/1
下载链接
链接失效反馈官方服务:
资源简介:
Introduction: This study aims to elucidate the spectrum of clinical manifestations, cytomorphology, immunophenotype, and the molecular genetic features of lymphoblastic lymphoma/acute lymphoblastic leukemia (LBL/ALL) in the context of serous effusions (SE). Methods: A retrospective analysis evaluated the cytomorphological features, immunophenotype, and the cyto-histological correlations of twenty-one LBL/ALL associated with SE. Concurrently, bone marrow (BM) aspiration samples were analyzed using an integrated approach, including flow cytometry, RT-PCR, next generation sequencing (NGS) or whole transcriptome sequencing (WTS). Results: Of the 21 cases of SE LBL/ALL, 16 cases were T-LBL/ALL and 5 cases were B-LBL/ALL. The cases included 17 pleural, 2 peritoneal, and 2 pericardial fluid samples. Both T-LBL/ALL and B-LBL/ALL in SE exhibit a blast-like morphology, characterized by small to medium size, irregular nuclear membranes, and inconspicuous nucleoli, alongside frequent nuclear fragmentation and apoptotic bodies. LBL/ALL express immaturity markers such as TdT (7/17, 41.2%), CD10 (6/12, 50%), CD43 (8/8, 100%), and CD99 (6/6, 100%). T-LBL/ALL and B-LBL/ALL specifically express T-cell markers [CD2 (3/6, 50%), CD3 (10/12, 83.3%), CD5 (2/11, 18.2%), CD7 (10/10, 100%)] or B-cell markers [CD20 (3/5, 60%), CD79a (4/4,100%), PAX5 (5/5, 100%)], respectively. A high proportion of primitive and immature lymphocytes exceeding 25% in BM was observed in T-LBL/ALL (5/7) and in one case of B-LBL/ALL. No BCR/ABL gene rearrangements were detected in any cases. Furthermore, fusion gene MLL::ENL and PLCALM::MLLT10, as well as mutations in genes including WT1, NOTCH1, PAX5, IKZF, ARID1A, BCOR, SETD2, ARID2, TET2, JAK3, NF1, and CEBPA, were identified in LBL/ALL through RT-PCR, NGS, or WTS. Conclusion: The integration of clinical manifestations, cytological evaluation, and gene expression profiles is instrumental in achieving accurate diagnosis, sub-classification, and prognosis of LBL/ALL within the context of SE.
提供机构:
Karger Publishers
创建时间:
2025-09-29



